Literature DB >> 27515251

Non-Hodgkin lymphoma and pre-existing conditions: spectrum, clinical characteristics and outcome in 213 children and adolescents.

Andishe Attarbaschi1, Elisa Carraro2, Oussama Abla3, Shlomit Barzilai-Birenboim4, Simon Bomken5, Laurence Brugieres6, Eva Bubanska7, Birgit Burkhardt8, Alan K S Chiang9, Monika Csoka10, Alina Fedorova11, Janez Jazbec12, Edita Kabickova13, Zdenka Krenova14, Jelena Lazic15, Jan Loeffen16, Georg Mann17, Felix Niggli18, Natalia Miakova19, Tomoo Osumi20, Leila Ronceray17, Anne Uyttebroeck21, Denise Williams22, Wilhelm Woessmann23, Grazyna Wrobel24, Marta Pillon2.   

Abstract

Children and adolescents with pre-existing conditions such as DNA repair defects or other primary immunodeficiencies have an increased risk of non-Hodgkin lymphoma. However, large-scale data on patients with non-Hodgkin lymphoma and their entire spectrum of pre-existing conditions are scarce. A retrospective multinational study was conducted by means of questionnaires sent out to the national study groups or centers, by the two largest consortia in childhood non-Hodgkin lymphoma, the European Intergroup for Childhood non-Hodgkin Lymphoma, and the international Berlin-Frankfurt-Münster Study Group. The study identified 213 patients with non-Hodgkin lymphoma and a pre-existing condition. Four subcategories were established: a) cancer predisposition syndromes (n=124, 58%); b) primary immunodeficiencies not further specified (n=27, 13%); c) genetic diseases with no increased cancer risk (n=40, 19%); and d) non-classifiable conditions (n=22, 10%). Seventy-nine of 124 (64%) cancer predispositions were reported in groups with more than 20 patients: ataxia telangiectasia (n=32), Nijmegen breakage syndrome (n=26), constitutional mismatch repair deficiency (n=21). For the 151 patients with a known cancer risk, 5-year event-free survival and overall survival rates were 40%±4% and 51%±4%, respectively. Five-year cumulative incidences of progression/relapse and treatment-related death as a first event were 22%±4% and 24%±4%, respectively. Ten-year incidence of second malignancy was 24%±5% and 7-year overall survival of the 21 patients with a second malignancy was 41%±11%. Patients with non-Hodgkin lymphoma and pre-existing conditions have an inferior survival rate with a large proportion of therapy-related deaths compared to patients with non-Hodgkin lymphoma and no pre-existing conditions. They may require special vigilance when receiving standard or modified/reduced-intensity chemotherapy or when undergoing allogeneic stem cell transplantation. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Year:  2016        PMID: 27515251      PMCID: PMC5479624          DOI: 10.3324/haematol.2016.147116

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  47 in total

1.  Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report.

Authors:  A Reiter; M Schrappe; W D Ludwig; M Tiemann; R Parwaresch; M Zimmermann; E Schirg; G Henze; G Schellong; H Gadner; H Riehm
Journal:  Blood       Date:  2000-01-15       Impact factor: 22.113

2.  Defining Why Cancer Develops in Children.

Authors:  John M Maris
Journal:  N Engl J Med       Date:  2015-11-18       Impact factor: 91.245

Review 3.  Pediatric leukemia predisposition syndromes: clues to understanding leukemogenesis.

Authors:  Alix E Seif
Journal:  Cancer Genet       Date:  2011-05

4.  Promising therapy results for lymphoid malignancies in children with chromosomal breakage syndromes (Ataxia teleangiectasia or Nijmegen-breakage syndrome): a retrospective survey.

Authors:  Klaus Bienemann; Birgit Burkhardt; Simon Modlich; Ulrike Meyer; Anja Möricke; Kirsten Bienemann; Christine Mauz-Körholz; Gabriele Escherich; Martin Zimmermann; Dieter Körholz; Gritta Janka-Schaub; Martin Schrappe; Alfred Reiter; Arndt Borkhardt
Journal:  Br J Haematol       Date:  2011-09-19       Impact factor: 6.998

5.  Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients.

Authors:  Catherine Patte; Anne Auperin; Mary Gerrard; Jean Michon; Ross Pinkerton; Richard Sposto; Claire Weston; Martine Raphael; Sherrie L Perkins; Keith McCarthy; Mitchell S Cairo
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

6.  Long-term results of AIEOP LNH-92 protocol for the treatment of pediatric lymphoblastic lymphoma: a report of the Italian Association of Pediatric Hematology and Oncology.

Authors:  Marta Pillon; Matilde Piglione; Alberto Garaventa; Valentino Conter; Maria Giuliano; Giampaolo Arcamone; Rossella Mura; Monica Cellini; Emanuele S G D'Amore; Stefania Varotto; Lara Mussolin; Angelo Rosolen
Journal:  Pediatr Blood Cancer       Date:  2009-12       Impact factor: 3.167

7.  Unique morphological spectrum of lymphomas in Nijmegen breakage syndrome (NBS) patients with high frequency of consecutive lymphoma formation.

Authors:  M Gładkowska-Dura; K Dzierzanowska-Fangrat; W T Dura; J H J M van Krieken; K H Chrzanowska; J J M van Dongen; A W Langerak
Journal:  J Pathol       Date:  2008-11       Impact factor: 7.996

Review 8.  Leukemia and lymphoma in ataxia telangiectasia.

Authors:  A M Taylor; J A Metcalfe; J Thick; Y F Mak
Journal:  Blood       Date:  1996-01-15       Impact factor: 22.113

9.  Non-Hodgkin lymphoma (NHL) in children with Nijmegen Breakage syndrome (NBS).

Authors:  Bozenna Dembowska-Baginska; Danuta Perek; Agnieszka Brozyna; Anna Wakulinska; Dorota Olczak-Kowalczyk; Malgorzata Gladkowska-Dura; Wieslawa Grajkowska; Krystyna H Chrzanowska
Journal:  Pediatr Blood Cancer       Date:  2009-02       Impact factor: 3.167

10.  Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report.

Authors:  S Goldman; L Smith; J R Anderson; S Perkins; L Harrison; M B Geyer; T G Gross; H Weinstein; S Bergeron; B Shiramizu; W Sanger; M Barth; J Zhi; M S Cairo
Journal:  Leukemia       Date:  2012-09-03       Impact factor: 11.528

View more
  19 in total

Review 1.  Primary immunodeficiencies and their associated risk of malignancies in children: an overview.

Authors:  Samuele Renzi; Karin Petra Sabine Langenberg-Ververgaert; Nicolas Waespe; Salah Ali; Jack Bartram; Orli Michaeli; Julia Upton; Michaela Cada
Journal:  Eur J Pediatr       Date:  2020-03-11       Impact factor: 3.183

2.  Primary central nervous system lymphoma: initial features, outcome, and late effects in 75 children and adolescents.

Authors:  Andishe Attarbaschi; Oussama Abla; Leila Ronceray; Shweta Bansil; Simon Bomken; Birgit Burkhardt; Francecso Ceppi; Alan K S Chiang; Hema Dave; Alina Fedorova; Michael Henry; Janez Jazbec; Edita Kabickova; Rishi S Kotecha; Jelena Lazic; Jan Loeffen; Natalia Miakova; Tomoo Osumi; Marta Pillon; Apostolos Pourtsidis; Charlotte Rigaud; Gevorg Tamamyan; Sneha Tandon; Anne Uyttebroeck; Jamie Verdu-Amoros; Wilhelm Woessmann; Grazyna Wrobel; Lisa Giulino-Roth
Journal:  Blood Adv       Date:  2019-12-23

Review 3.  T-cell lymphoblastic lymphoma and leukemia: different diseases from a common premalignant progenitor?

Authors:  Emma Kroeze; Jan L C Loeffen; Vera M Poort; Jules P P Meijerink
Journal:  Blood Adv       Date:  2020-07-28

4.  Comprehensively evaluating cancer survival in children with birth defects: a population-based assessment.

Authors:  Amanda E Janitz; Jeremy M Schraw; Chao Xu; Philip J Lupo
Journal:  Cancer Causes Control       Date:  2022-01-11       Impact factor: 2.506

5.  Molecular characterization of an embryonal rhabdomyosarcoma occurring in a patient with Kabuki syndrome: report and literature review in the light of tumor predisposition syndromes.

Authors:  Sietse M Aukema; Selina Glaser; Mari F C M van den Hout; Sonja Dahlum; Marinus J Blok; Morten Hillmer; Julia Kolarova; Raf Sciot; Dina A Schott; Reiner Siebert; Constance T R M Stumpel
Journal:  Fam Cancer       Date:  2022-07-19       Impact factor: 2.446

6.  Second malignant neoplasms after treatment of non-Hodgkin's lymphoma-a retrospective multinational study of 189 children and adolescents.

Authors:  Andishe Attarbaschi; Elisa Carraro; Leila Ronceray; Mara Andrés; Shlomit Barzilai-Birenboim; Simon Bomken; Laurence Brugières; Birgit Burkhardt; Francesco Ceppi; Alan K S Chiang; Monika Csoka; Alina Fedorova; Janez Jazbec; Edita Kabickova; Jan Loeffen; Karin Mellgren; Natalia Miakova; Olga Moser; Tomoo Osumi; Apostolos Pourtsidis; Charlotte Rigaud; Anne Uyttebroeck; Wilhelm Woessmann; Marta Pillon
Journal:  Leukemia       Date:  2020-05-11       Impact factor: 11.528

7.  DNA damage response defect in Williams-Beuren syndrome.

Authors:  David Guenat; Giuseppe Merla; Eric Deconinck; Christophe Borg; Pierre-Simon Rohrlich
Journal:  Int J Mol Med       Date:  2017-01-17       Impact factor: 4.101

Review 8.  Current Understanding and Future Research Priorities in Malignancy Associated With Inborn Errors of Immunity and DNA Repair Disorders: The Perspective of an Interdisciplinary Working Group.

Authors:  Simon Bomken; Jutte van der Werff Ten Bosch; Andishe Attarbaschi; Chris M Bacon; Arndt Borkhardt; Kaan Boztug; Ute Fischer; Fabian Hauck; Roland P Kuiper; Tim Lammens; Jan Loeffen; Bénédicte Neven; Qiang Pan-Hammarström; Isabella Quinti; Markus G Seidel; Klaus Warnatz; Claudia Wehr; Arjan C Lankester; Andrew R Gennery
Journal:  Front Immunol       Date:  2018-12-12       Impact factor: 7.561

9.  Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma.

Authors:  Cristina López; Kortine Kleinheinz; Sietse M Aukema; Marius Rohde; Stephan H Bernhart; Daniel Hübschmann; Rabea Wagener; Umut H Toprak; Francesco Raimondi; Markus Kreuz; Sebastian M Waszak; Zhiqin Huang; Lina Sieverling; Nagarajan Paramasivam; Julian Seufert; Stephanie Sungalee; Robert B Russell; Julia Bausinger; Helene Kretzmer; Ole Ammerpohl; Anke K Bergmann; Hans Binder; Arndt Borkhardt; Benedikt Brors; Alexander Claviez; Gero Doose; Lars Feuerbach; Andrea Haake; Martin-Leo Hansmann; Jessica Hoell; Michael Hummel; Jan O Korbel; Chris Lawerenz; Dido Lenze; Bernhard Radlwimmer; Julia Richter; Philip Rosenstiel; Andreas Rosenwald; Markus B Schilhabel; Harald Stein; Stephan Stilgenbauer; Peter F Stadler; Monika Szczepanowski; Marc A Weniger; Marc Zapatka; Roland Eils; Peter Lichter; Markus Loeffler; Peter Möller; Lorenz Trümper; Wolfram Klapper; Steve Hoffmann; Ralf Küppers; Birgit Burkhardt; Matthias Schlesner; Reiner Siebert
Journal:  Nat Commun       Date:  2019-03-29       Impact factor: 14.919

10.  The paradigm of hematological malignant versus non-malignant manifestations, driven by primary immunodeficiencies: a complex interplay.

Authors:  C Kelaidi; V Tzotzola; S Polychronopoulou
Journal:  Fam Cancer       Date:  2021-06-15       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.